



UNIVERSITI PUTRA MALAYSIA

**IMMUNOMODULATORY ACTIVITY OF MANNHEIMIA HAEMOLYTICA
A2 LIPOPOLYSACCHARIDE**

AZLINA BT MOHD SALIM

FPSK (M) 2003 8

**IMMUNOMODULATORY ACTIVITY OF *MANNHEIMIA HAEMOLYTICA*
A2 LIPOPOLYSACCHARIDE**

By

AZLINA BT MOHD SALIM

**Thesis submitted to the School of Graduate Studies, Universiti Putra
Malaysia, in fulfillment of the Requirements for the Degree of
Master of Science**

September 2003



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfillment of the requirement for the degree of Master of Science.

**IMMUNOMODULATORY ACTIVITY OF *MANNHEIMIA HAEMOLYTICA*
A2 LIPOPOLYSACCHARIDE**

By

AZLINA BT MOHD.SALIM

September 2003

Chairman : Associate Professor Daud Ahmad Israf Ali, Ph.D.

Faculty : Medicine and Health Science

Bacterial lipopolysaccharides (LPS) are endotoxins. However, there ample evidence to support its role in immunomodulation. In fact LPS is commonly used as a B cell mitogen. The activity of LPS from different genera of bacteria varies considerably which makes generalisation of characteristics difficult. Despite their lethal consequences, the LPS of *Mannheimia haemolytica* A2 have not been tested for immunomodulatory activity. Therefore, the objective of this study is to investigate the adjuvant properties of LPS from *Mannheimia haemolytica* A2 upon peripheral and mucosal immunity toward protein antigen.

The experimental results indicate that, the group of mice that received 10 µg LPS in oil induced anti-BSA IgG response in serum and pulmonary antibody response when administered intraperitoneally. However, in the IgG and IgA intestinal antibody response, mice received 10 µg LPS without oil showed significantly high compared to controls



($p \leq 0.05$). This indicates that LPS can be used as oral adjuvant to enhance response at mucosal level. For the oral immunisation, the specific anti-OVA IgG titre in serum and IgA levels in the intestinal fluid were significantly high in group that received 500 μg LPS. The oral administration of 500 μg LPS also increased the number of anti-OVA ASC (antigen secreting cell) observed in spleen, mesentric lymph node and Peyer's patch. Hence, LPS from *Mannheimia haemolytica* A2 does stimulate peripheral and mucosal immune responses to an unrelated antigen.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Master Sains.

**AKTIVITI IMUNOMODULATOR MEMBRAN LIPOPOLISAKARIDA
DARIPADA BAKTERIA *MANNHEIMIA HAEMOLYTICA* A2**

Oleh

AZLINA BT MOHD.SALIM

September 2003

Pengerusi : Profesor Madya Daud Ahmad Israf Ali, Ph.D.

Fakulti : Perubatan dan Sains Kesihatan

Lipopolisakarida (LPS) dalam bakteria merupakan sejenis endotoksin. Walaubagaimanapun, terdapat bukti yang menyatakan bahawa LPS mempunyai peranan sebagai imunomodulator di mana LPS biasanya bertindak sebagai mitogen dalam sel B. Aktiviti LPS daripada pelbagai genera bakteria sangat meluas sehingga agak sukar untuk membuat pengkelasan. Selain daripada mempunyai sifat-sifat toksin, ujikaji terhadap aktiviti imunomodulator masih belum dijalankan terutama LPS dari jenis *Mannheimia haemolytica* A2. Oleh yang demikian, di dalam eksperimen ini, beberapa ujikaji telah sama ada LPS dari jenis *Mannheimia haemolytica* A2 boleh bertindak sebagai 'adjuvant' di dalam sistem periperal dan mukosa terhadap antigen.

Hasil kajian menunjukkan bahawa, kumpulan mencit yang diberi suntikan intraperitoneal campuran 10 µg LPS dan minyak menghasilkan antibodi anti-BSA IgG yang tinggi dalam serum dan



ekstrak pulmonari. Walau bagaimanapun, di dalam ekstrak intestin kandungan antibodi IgG dan IgA telah menunjukkan peningkatan yang baik daripada kumpulan mencit yang disuntik dengan 10 µg LPS tanpa minyak ($p \leq 0.05$) berbanding kawalan. Ini menunjukkan bahawa LPS boleh diberi secara oral untuk merangsang pembentukan antibodi di dalam sistem mukosa. Keputusan eksperimen menunjukkan bahawa 500 µg LPS yang diberi secara oral kepada kumpulan mencit telah meningkatkan antibodi anti-OVA IgG dalam serum dan IgA dalam ekstrak intestin. Selain daripada meningkatkan paras antibodi, bilangan sel-sel limfoid (anti-OVA ASC) juga meningkat terutama di dalam organ limpa, sel-sel mesentrik dan Peyer's patch. Keputusan ujikaji jelas menunjukkan bahawa LPS dari bakteria jenis *Mannheimia haemolytica* A2 boleh merangsang tindakbalas imun di dalam sistem periperiferal dan mukosa terhadap antigen.

ACKNOWLEDGEMENT

I would like to acknowledge the following people who made this work possible.

I thank my supervisor, Associate Professor Dr. Daud Ahmad Israf Ali for all the guidance and encouragement through my academic studies at Universiti Putra Malaysia.

I would like to thank the members of my supervisory committee, Associate Professor Dr. Abdul Rahman Omar and Professor Dr. Mohd Zamri Saad for inviting me to work in their laboratories and invaluable help in providing the samples used in this thesis.

Finally, I thank my colleagues and laboratory partners, Nor Azura and Hartina for their help and great cooperation working with me in the laboratory.



TABLE OF CONTENTS

	Page
ABSTRACT	ii
ABSTRAK	iv
ACKNOWLEDGEMENTS	vi
APPROVAL	vii
DECLARATION	ix
LIST OF TABLES	xiii
LIST OF FIGURES	xiv
LIST OF ABBREVIATIONS	xviii
CHAPTER	
1 INTRODUCTION	1
2 LITERATURE REVIEW	4
2.1 Adjuvants	4
2.1.1 Monophosphoryl lipid A (MPL)	6
2.1.2 Titermax®	7
2.1.3 Saponins	8
2.1.3.1 Structure of Quillaja Saponins	9
2.1.4 Liposome	10
2.1.5 Muramyl Dipeptide (MPD) and derivatives	11
2.1.6 Bacterial Lipopolysaccharides	13
2.1.7 Mechanism of LPS adjuvanticity	17
2.1.8 Cholera toxin (CT)	20
2.1.9 <i>E. Coli</i> heat-labile enterotoxin (LT)	21
2.1.10 Oral immunisation	22
3 Extraction of Lipopolysaccharides (LPS) from <i>Mannheimia haemolytica</i> A2	26
Introduction	26
3.1 Materials and Methods	27
3.1.1 Blood agar preparation	27
3.1.2 Brain Heart Infusion (BHI) broth preparation	27
3.1.3 Bacteria strains and growth conditions	28
3.1.4 Lipopolysaccharides extraction	28



3.1.5	Protein Assay	29
3.1.6	Gel preparation	30
	3.1.6.1 Separating gel	30
	3.1.6.2 Stacking gel	30
3.1.7	Sodium Dodecyl Sulphate Polyacrylamide gel Electrophoresis (SDS-PAGE)	30
3.1.8	Silver staining	31
3.2	Result	32
	3.2.1 Protein estimation	32
	3.2.2 Silver staining	33
3.3	Discussion	34
4	Enhancement of anti-BSA immune response via Intraperitoneal immunisation with BSA coadministered with <i>Mannheimia</i> <i>haemolytica</i> A2 LPS	36
	Introduction	36
4.1	Materials and Method	37
	4.1.1 LPS extraction and purification	37
	4.1.2 Animals	37
	4.1.3 Preparation of immunogen/adjuvant complex	37
	4.1.4 Immunisation protocol	38
	4.1.5 Sample collection	38
	4.1.6 Enzyme linked immunosorbent assay (ELISA) for determination of serum antibodies	40
	4.1.7 Enzyme linked immunosorbent assay (ELISA) for determination of intestinal and	41
	4.1.8 Enzyme linked immunosorbent assay (ELISA) for determination of coproantibodies	43
	4.1.9 Statistical analysis	43
4.2	Results	44
	4.2.1 Serum antibody response	44
	4.2.2 Intestinal antibody response	44
	4.2.3 Pulmonary antibody response	45
	4.2.4 Faecal IgA response	45
4.3	Discussion	58

5	Enhancement of anti-OVA immune responses via oral boosting with OVA co-administered with <i>Manheimia haemolytica</i> A2 LPS	61
	Introduction	61
5.1	Materials and Methods	63
	5.1.1 Mice	63
	5.1.2 Immunisation	63
	5.1.3 Sample collection	63
	5.1.4 In-vitro restimulation of lymphocytes	66
	5.1.5 Enzyme linked immunosorbent assay (ELISA) to measure specific IgG responses	66
	5.1.6 Enzyme linked immunosorbent assay (ELISA) to measure specific IgA responses	67
	5.1.7 Enzyme linked immunospot assay (ELISPOT) to measure antibody secreting cells	69
	5.1.8 Statistical analysis	70
5.2	Results	71
	5.2.1 Serum antibody response	71
	5.2.2 Intestinal antibody response	71
	5.2.3 Faecal IgA response	76
	5.2.4 Pulmonary antibody response	76
	5.2.5 Anti-OVA antibody secreting cells (ASCs) in SP, PP and MLN	76
5.3	Discussion	82
6	GENERAL DISCUSSION AND CONCLUSION	85
	REFERENCES	88
	APPENDICES	99
	BIODATA OF THE AUTHOR	115



LIST OF TABLES

		Page
Table 2.1	Side effect of FIA (Rajesh <i>et al.</i> , 1993)	6
Table 2.2	Biological activities of lipid A or LPS	16
Table 4.1	EXPERIMENTAL DESIGN	39
Table 5.1	EXPERIMENTAL DESIGN	65
Table 6.1	Data summarised the adjuvant effects of LPS from <i>Mannheimia haemolytica</i> A2. The group of mice that received 10 µg LPS in oil for IP and 500 µg for oral immunisation showed significantly high in antibody titres ($p \leq 0.05$)	86



LIST OF FIGURES

		Page
Figure 2.1	Gram-negative bacteria and cell membrane (Nakano & Matsuura, 1995)	14
Figure 3.1	Detection of lipopolysaccharides by silver stained followed by Coomassie blue staining. Samples were analysed on 12% SDS-polyacrylamide gel electrophoresis. Lane 1, 10 µg <i>S. typhimurium</i> LPS smear (control); lane 2, 10 µg <i>E. coli</i> 0111:B4 LPS smear (control); lanes 3, 4 and 5, <i>M. haemolytica</i> LPS smears at 10, 5 and 1µg respectively. The molecular weight protein markers (kDa) were just to detect whether there was a protein contamination on the gel and LPS samples	33
Figure 4.1(a)	Peripheral anti-BSA IgG antibody responses in mice. Mice were immunised with BSA-FCA ■, BSA 1 µg LPS in oil ✕, BSA 10 µg LPS in oil * and 100 µg BSA as a control ◆	46
Figure 4.1(b)	Peripheral anti-BSA IgG antibody responses in mice. Mice were immunised with BSA-FCA ■, BSA 1 µg LPS without oil ▲, BSA 10 µg LPS without oil △ and 100 µg BSA as a control ◆	47
Figure 4.2(a)	Peripheral anti-BSA IgA antibody responses in mice. Mice were immunised with BSA-FCA □, BSA 1 µg LPS in oil ◆, BSA 10 µg LPS in oil △ and 100 µg BSA as a control *	48
Figure 4.2(b)	Peripheral anti-BSA IgA antibody responses in mice. Mice were immunised with BSA-FCA □, BSA 1 µg LPS without oil ▲, BSA 10 µg LPS without oil ■ and 100 µg BSA as a control *	49

	Page
Figure 4.3(a) Peripheral anti-BSA IgM antibody responses in mice. Mice were immunised with BSA-FCA ◆, BSA 1 µg LPS in oil ◇, BSA 10 µg LPS in oil △ and 100 µg BSA as a control *	50
Figure 4.3(b) Peripheral anti-BSA IgM antibody responses in mice. Mice were immunised with BSA-FCA ◆, BSA 1 µg LPS without oil ◇, BSA 10 µg LPS without oil ▲ and 100 µg BSA as a control *	51
Figure 4.4 Intestinal anti-BSA IgA antibody responses of mice immunised with 100 µg BSA with LPS or without LPS. Mice receiving 10 µg LPS showed significant increase compared with BSA/Freund's and other groups ($p \leq 0.05$)	52
Figure 4.5 Intestinal anti-BSA IgG antibody responses of mice immunised with 100 µg BSA with LPS or without LPS. Mice receiving 10 µg LPS showed significant increase compared with BSA/Freund's and other groups ($p \leq 0.05$)	53
Figure 4.6 Pulmonary anti-BSA IgG antibody responses of mice immunised with 100 µg BSA with LPS or without LPS. Mice receiving 10 µg LPS showed significant increase compared with group that received 1µg LPS with or without oil ($p \leq 0.05$)	54
Figure 4.7 Pulmonary anti-BSA IgA antibody responses of mice immunised with 100 µg BSA with LPS or without LPS. The result showed that there was no significant different among all groups	55
Figure 4.8(a) Feecal extract anti-BSA IgA antibody responses of mice immunised with BSA-FCA ■, BSA-1 µg LPS in oil △, BSA-10 µg LPS in oil *, 100 µg BSA ▲ and PBS ◆	56

	Page
Figure 4.8(b) Feacal extract anti-BSA IgA antibody responses of mice immunised with BSA-FCA ■, BSA-1 µg LPS without oil Δ, BSA-10 µg LPS without oil *, 100 µg BSA ▲ and PBS ◆	57
Figure 5.1 Peripheral anti-OVA IgG antibody responses in mice. Mice were immunised with 1 mg OVA for ip and 10 mg OVA for oral with or without LPS as described in Table 5.1	72
Figure 5.2 Peripheral anti-OVA IgA antibody responses in mice. Mice were immunised with 1 mg OVA for ip and 10 mg OVA for oral with or without LPS as described in Table 5.1	73
Figure 5.3 Intestinal anti-OVA IgA antibody responses in mice immunised with 10 mg OVA with or without LPS. The concentration of IgA in intestinal washing were significantly increased in mice that received 500 µg LPS compared with control (p≤0.05)	74
Figure 5.4 Intestinal anti-OVA IgG antibody responses in mice immunised with 10 mg OVA with 10 µg CT were higher than all treated groups but no significant difference between controls and group that received 500 µg LPS	75
Figure 5.5 Feacal extract anti-OVA IgA antibody responses in mice. Mice were immunised with 10 mg OVA orally with 100 µg LPS, OVA-500 µg LPS, OVA-CT and OVA alone as a control	77
Figure 5.6 Pulmonary anti-OVA IgG antibody responses in mice. Mice were immunised with 10 mg OVA orally with 100 µg LPS, OVA-500 µg LPS, OVA-CT and OVA alone as a control	78

	Page
Figure 5.7 Anti-OVA IgA and IgG secreting cells/ 10^6 cells in spleen (SP) from mice immunised orally with 10 mg OVA-100 μ g LPS, OVA-500 μ g LPS, OVA-CT and OVA alone as a control	79
Figure 5.8 Anti-OVA IgA and IgG secreting cells/ 10^6 cells in Peyer's patch (PP) from mice immunised orally with 10 mg OVA-100 μ g LPS, OVA-500 μ g LPS, OVA-CT and OVA alone as a control	80
Figure 5.9 Anti-OVA IgA and IgG secreting cells/ 10^6 cells in Mesentric lymph node (MLN) from mice immunised orally with 10 mg OVA-100 μ g LPS, OVA-500 μ g LPS, OVA-CT and OVA alone as a control	81



LIST OF ABBREVIATIONS

FCA	Freund's complete adjuvant
FIA	Freund's incomplete adjuvant
LPS	Lipopolysaccharides
DAG	2,3 -dideoxy-D-glucose
OMPs	Outer membrane proteins
BSA	Bovine serum albumin
OVA	Ovalbumin
MPL	Monophosphoryl lipid A
MDP	Muramyl dipeptide
CWS	Cell wall skeleton
EAU	Experimental autoimmune ureoretinitis
CTL	Cytotoxic T lymphocyte
TNF	Tumour necrosis factor
IL	Interleukin
IFN	Interferon
APC	Antigen presenting cell
CT	Cholera toxin
SDS-PAGE	Sodium dodecyl sulphate polyacrylamide gel electrophoresis
BHI	Brain heart infusion
TEMED	N-N-N'-N'-tetramethylethylenediamine
TNP	Trinitrophenyl hepten
PBS	Phosphate buffered saline
PMSF	Phenylmethylsulfonyl fluoride
ELISA	Enzyme linked immunosorbent assay
TMB	Tetramethylbenzidine
LT	Heat-labile enterotoxin
GALT	Gut-associate lymphoid tissues
UPM	Universiti Putra Malaysia
IP	Intraperitoneal
HRPO	Horseradish peroxidase
ELISPOT	Enzyme linked immunospot assay
AEC	Amino ethyl carbazole



CHAPTER I

INTRODUCTION

Immunomodulators are compounds that can cause either suppression or potentiation of the immune system. Immunomodulators are used to stimulate immune responses to vaccines. Adjuvants are generally considered to be materials that are added to vaccines with the intent of potentiating the immune response so that a greater amount of antibody is produced. The most common adjuvants that are safe for human use are aluminium hydroxide, aluminium phosphate and calcium phosphate (Edelman, 1980). Adjuvants that have been used for research purposes are oil emulsions which were first used by Le Moignic and Pinoy (1916), who found that a suspension of killed *Salmonella typhimurium* in mineral oil increased the immune response. Freund's complete adjuvant (FCA), a water mineral oil emulsion with killed mycobacterium is used extensively to augment the immune response of laboratory animals for experimental purposes. Freund's incomplete adjuvant (FIA) which is water in oil emulsion without mycobacterium is used successfully in veterinary rabies, parainfluenza and Newcastle disease. There are also other adjuvants derived from other bacteria and their products.



They play an important role in the immune response. The common bacterial used as adjuvants mainly for experimental purposes include mycobacterium, *Corynebacterium parvum* or *Corynebacterium granulosum*, *Bordetella pertussis* and lipopolysacharides (Rajesh *et al.*, 1993).

Lipopolysacharides (LPS) are common bacterial products that can be used as adjuvants. It is a constituent of the outer membrane of gram-negative bacteria that contains 2,3-dideoxy-D-glucose (DAG), an amino sugar attached to a lipid A backbone. LPS has long been known to be a potent modulator of immune reactions such as B cell mitogenicity, polyclonal antibody synthesis, immunogenicity, adjuvanticity, macrophage activation, monokine secretion and regulation of IgA responses (Qureshi *et al.*, 1990). LPS also induces regression of spontaneous, induced and transplanted tumours in laboratory animals. Its toxicity which involves pyrogenicity, tumour necrosis and lethality has limited exploration of its therapeutic potential in man. However, studies have shown that the toxic compound of the LPS molecule can be cleaved chemically (Ribi *et al.*, 1986). The dose of LPS and the time of exposure will determine the resultant effects that will be seen in the host. It has been shown to effect on B cell but not on T lymphocytes. LPS has been suggested to bind non-specifically to the cell surface followed by intercalation of its hydrophobic lipid A moiety into the plasma membrane (Jacobs, 1992). Others have implicated the involvement of specific receptors on the surface (Tahiri & Chaby, 1990). Recently, it has



been reported that the existence of membrane-associated LPS and lipid A-specific binding proteins on responsive cells, including macrophages, lymphocytes and B cells (Hara Kuge *et al.*, 1990).

There are many gram-negative bacteria that have been used as a source of LPS, particularly members of the enterobacteriaceae {*Salmonella*, *Shigella*, *Escherichia*, *Proteus*, *Pseudomonas*, *Klebsiella*, *Mannheimia* (*Pasteurella*)}. *Mannheimia haemolytica* serotype A2 is the most commonly occurring serotype associated with pneumonic pasteurellosis in cattle and sheep. Immunological studies have been done to determine responses in the respiratory tract using killed *M. haemolytica* A2 (Zamri *et al.*, 1999). Although experimental vaccines against pneumonic pasteurellosis have been done including both live and killed bacteria (Purdy *et al.*, 1986), research has attempted to identify important immunogenic components of *M. haemolytica* such as iron-regulated outer-membrane proteins (OMPs) (Gilmor *et al.*, 1991), carbohydrate-protein subunits (Lesley *et al.*, 1985) and LPS (Confer *et al.*, 1986). The immunomodulatory properties of LPS from *M. haemolytica* A2 have not been studied despite being an important pathogen of livestock. Therefore, the objectives of the study are:-

1. To extract and purify LPS from *Mannheimia haemolytica* A2.
2. To determine the immunostimulatory effect of *M. haemolytica* A2 LPS upon peripheral and mucosal immunity toward model protein antigens such as bovine serum albumin (BSA) and ovalbumin (OVA).



CHAPTER 2

LITERATURE REVIEW

2.1 Adjuvants

The response to an immunogen can be enhanced by the use of adjuvants. Adjuvants are compound that potentiate the immune response when mixed and administered with antigen. They enhance and prolong antibody production and increase effector cell counts (Coleman *et al.*, 1992). From this definition, it is obvious that adjuvants are useful and necessary components of the development of vaccines. An adjuvant must be able to increase both amount and duration of antibody and T helper cell response. The mode of action of adjuvants was summarised by Chedid *et al.*, (1975). First, the formation of a depot of antigen at the site of inoculation which is slowly released. Secondly, the presentation of antigen to immunocompetent cells and the production of different lymphokines such as various interleukins and tumour necrosis factor.

It has long been known that many adjuvants are surface-active agents (Allison, 1979). The importance of surface activity in adjuvanticity has been confirmed with modern adjuvants. Saponins, lipid A and muramyl dipeptide (MDP) derivatives are all surface active



in that they consist of discrete hydrophilic and hydrophobic domains. With the use of adjuvants, less antigen is required, thus reducing vaccine production cost (Rajesh *et al.*, 1993). For many years there has been a search to find adjuvants with the ability to potentiate the immune response but with minimal side effects. Freund's complete adjuvant (FCA) is one of the most potent oil adjuvants described so far and used extensively to augment the immune response of laboratory animals for experimental purposes. FCA as originally formulated was too toxic to be used in human. The water in mineral oil emulsion without Mycobacteria is known as Freund's incomplete adjuvant (FIA). FIA was used successfully in a number of veterinary vaccines including foot-and-mouth disease, rabies, parainfluenza and Newcastle disease. FIA has been used in human, particularly with influenza and killed poliomyelitis vaccines by enhancing the immunogenicity of the vaccines (Salk, 1977). However, FIA is unsuitable for routine human application because of previously reported side effects (Table 2.1). From these classical adjuvants, there are many alternative adjuvant that have been used for many years such as monophosphoryl lipid A (MPL), Titermax[®], saponins, liposome, muramyl dipeptide (MDP), lipopolysaccharides (LPS), cholera toxin and heat labile enterotoxin.



Table 2.1 : Side effect of FIA (Rajesh *et al.*, 1993)

Local reaction
Sterile abscesses and cysts
Granulomas
Inflammation
Carcinogenicity
Oil induced neoplasm in mice
Arlacel A induced carcinogenicity in mice

2.1.1 Monophosphoryl lipid A (MPL)

MPL is a non-toxic lipid A with the lack of phosphate on the reducing end of the disaccharide backbone which has 1000-fold less toxic than endotoxin (Ribi, 1984). MPL has immunostimulatory activities such as B cell mitogenicity, activation of macrophages, colony-stimulating activity and the induction of interleukin-1 (IL-1) production by human monocytes (Rudbach & Cantrell, 1990). Tomai *et al.*, (1987) showed that MPL has an adjuvant activity with poly-L-lysine antigen in LPS-hyporesponsive C3H/HeJ and C57BL/10ScN mice and in aging BALB/c mice, which have a low capacity to produce antibody, when examined by a modified haemolytic plaque assay. They also reported an adjuvant effect to sheep red blood cell (SRBC) antigen in young and ageing mice (Johnson *et al.*, 1987). Schneerson *et al.*, (1991) also reported that both the primary and secondary serum antibody responses to the capsular polysaccharides (CP) antigens in mice were stimulated